Notable Wednesday Option Activity: CUBI, VKTX, VZ

Viking Therapeutics (VKTX) and Verizon Communications (VZ) are experiencing notable options trading activity, with volumes representing nearly half of their respective average daily stock trading volumes. VKTX options volume reached 18,955 contracts, or 49.6% of its average daily share volume, driven by significant interest in the July 2025 $30 strike call option. Concurrently, VZ saw 85,503 options contracts trade, equating to 48.3% of its average daily share volume, with the July 2025 $43 strike call option attracting particularly high volume. This elevated activity in specific long-dated call options suggests considerable speculative or hedging interest in potential future price movements for both companies.

Analysis

Viking Therapeutics (VKTX) and Verizon Communications (VZ) are both exhibiting unusually high options market activity, indicating significant investor positioning. For VKTX, options volume reached 18,955 contracts, equivalent to a substantial 49.6% of its average daily share volume. This activity was heavily concentrated in the July 2025 $30 strike call options. Similarly, VZ's options volume of 85,503 contracts accounted for 48.3% of its average daily share turnover, with a notable focus on the July 2025 $43 strike calls. The concentration in these specific long-dated call options, expiring over a year from now, suggests that market participants are not merely engaging in short-term speculation but are placing bets on or hedging against significant price movements over a longer horizon. This elevated flow in derivatives, relative to the underlying equity, points toward heightened expectations for future catalysts or a fundamental re-rating for both companies.

Key Decisions for Investors

• Investors should monitor the open interest and volume trends in the specified July 2025 call options for both VKTX and VZ to gauge whether this positioning represents a sustained institutional view or a short-term trade.
• The significant call volume implies an expectation of future upside or volatility, warranting a review of potential company-specific catalysts, such as clinical trial data for VKTX or strategic developments for VZ, that could unfold before the options' expiration.